{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:30:25Z","timestamp":1788863425350,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1245\/s10434-018-6433-6","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T16:11:13Z","timestamp":1521562273000},"page":"1768-1774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases"],"prefix":"10.1245","volume":"25","author":[{"given":"David L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin H. L.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Koujanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn A.","family":"Beyfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simron","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten","family":"Myrehaug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Hallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"6433_CR1","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063\u201372.","journal-title":"J Clin Oncol."},{"key":"6433_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589\u2013597.","journal-title":"Cancer."},{"key":"6433_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/annonc\/mds276","volume":"24","author":"H Sorbye","year":"2013","unstructured":"Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24:152\u2013160.","journal-title":"Ann Oncol."},{"key":"6433_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","volume":"18","author":"DM Halperin","year":"2017","unstructured":"Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18:525\u2013534.","journal-title":"Lancet Oncol."},{"key":"6433_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","volume":"41","author":"JL Beaumont","year":"2012","unstructured":"Beaumont JL, Cella D, Phan AT, Choi S, Liu Z, Yao JC. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41:461\u2013466.","journal-title":"Pancreas."},{"key":"6433_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172\u2013185.","journal-title":"Neuroendocrinology."},{"key":"6433_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1245\/ASO.2006.03.071","volume":"13","author":"DA Osborne","year":"2006","unstructured":"Osborne DA, Zervos EE, Strosberg J, Strosberg J, Boe BA, Malafa M, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13: 572\u2013581. \n                    https:\/\/doi.org\/10.1245\/aso.2006.03.071","journal-title":"Ann Surg Oncol."},{"key":"6433_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/j.1477-2574.2010.00198.x","volume":"12","author":"ES Glazer","year":"2010","unstructured":"Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB. 2010;12:427\u2013433.","journal-title":"HPB."},{"key":"6433_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.surg.2004.11.007","volume":"137","author":"D Elias","year":"2005","unstructured":"Elias D, Sideris L, Liberale G, Ducreux M, Malka D, Lasser P, et al. Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery. 2005;137:411\u2013416.","journal-title":"Surgery."},{"key":"6433_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.surg.2013.05.030","volume":"155","author":"D Elias","year":"2014","unstructured":"Elias D, David A, Sourrouille I, Honor\u00e9 C, Go\u00e9r\u00e9 D, Dumont F, et al. Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases). Surgery. 2014;155:5\u201312.","journal-title":"Surgery."},{"key":"6433_CR11","unstructured":"Bosman FT, World Health Organization, International Agency for Research on Cancer, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon: International Agency for Research on Cancer; 2010."},{"key":"6433_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u2013213.","journal-title":"Ann Surg."},{"key":"6433_CR13","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl. 1990. 2009;45:228\u2013247."},{"key":"6433_CR14","unstructured":"Cancer Care Ontario. ontario cancer registry \u2013 CCO. 2017. \n                    https:\/\/www.cancercare.on.ca\/ocs\/csurv\/ocr\/\n                    \n                  . Accessed 22 Aug 2017."},{"key":"6433_CR15","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1200\/JOP.2010.000098","volume":"6","author":"S Singh","year":"2010","unstructured":"Singh S, Law C. Multidisciplinary reference centers: the care of neuroendocrine tumors. J Oncol Pract. 2010;6:e11-6.","journal-title":"J Oncol Pract."},{"key":"6433_CR16","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.1503\/cjs.014112","volume":"57","author":"A Nadler","year":"2014","unstructured":"Nadler A, Cukier M, Milot L, Singh S, Law C. Hepatic parenchymal preserving technique in the management of diffuse bilateral neuroendocrine tumour liver metastases: a feasible approach. Can J Surg. 2014;57:E2\u2013E8.","journal-title":"Can J Surg."},{"key":"6433_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u2013481.","journal-title":"J Am Stat Assoc."},{"key":"6433_CR18","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.2967\/jnumed.113.135855","volume":"55","author":"Z Devcic","year":"2014","unstructured":"Devcic Z, Rosenberg J, Braat AJA, Techasith T, Banerjee A, Sze DY, et al. The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. J Nucl Med. 2014;55:1404\u20131410.","journal-title":"J Nucl Med."},{"key":"6433_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.surg.2007.01.036","volume":"142","author":"PJ Mazzaglia","year":"2007","unstructured":"Mazzaglia PJ, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery. 2007;142:10\u201319.","journal-title":"Surgery."},{"key":"6433_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364: 501\u201313.","journal-title":"N Engl J Med."},{"key":"6433_CR21","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet Lond Engl. 2016;387:968\u2013977.","journal-title":"Lancet Lond Engl."},{"key":"6433_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177 Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125\u2013135.","journal-title":"N Engl J Med."},{"key":"6433_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","volume":"35","author":"MH Kulke","year":"2017","unstructured":"Kulke MH, H\u00f6rsch D, Caplin ME, Anthony LB, Bergsland E, \u00d6berg K, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35:14\u201323.","journal-title":"J Clin Oncol."},{"key":"6433_CR24","doi-asserted-by":"publisher","first-page":"E398","DOI":"10.1503\/cmaj.160771","volume":"189","author":"MJ Raphael","year":"2017","unstructured":"Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ. 2017;189:E398\u2013E404.","journal-title":"CMAJ."},{"key":"6433_CR25","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","volume":"128","author":"IM Modlin","year":"2005","unstructured":"Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717\u201351.","journal-title":"Gastroenterology."},{"issue":"1","key":"6433_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1200\/JGO.2015.002980","volume":"3","author":"S Singh","year":"2016","unstructured":"Singh S, Granberg D, Wolin E, Warner R, Sissons M, Kolarova T, et al. Patient-reported burden of a neuroendocrine tumor (net) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2016;3(1):43\u201353.","journal-title":"J Glob Oncol."},{"key":"6433_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jamcollsurg.2015.03.055","volume":"221","author":"GB Deutsch","year":"2015","unstructured":"Deutsch GB, Lee JH, Bilchik AJ. Long-term survival with long-acting somatostatin analogues plus aggressive cytoreductive surgery in patients with metastatic neuroendocrine carcinoma. J Am Coll Surg. 2015;221: 26\u201336.","journal-title":"J Am Coll Surg."},{"key":"6433_CR28","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1245\/s10434-017-5839-x","volume":"24","author":"M Fairweather","year":"2017","unstructured":"Fairweather M, Swanson R, Wang J, Brais LK, Dutton T, Kulke MH, et al. Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol. 2017;24: 2319\u20132325.","journal-title":"Ann Surg Oncol."},{"key":"6433_CR29","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/cncr.28760","volume":"121","author":"A Frilling","year":"2015","unstructured":"Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer. 2015;121: 1172\u20131186.","journal-title":"Cancer."},{"key":"6433_CR30","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1245\/s10434-011-1832-y","volume":"18","author":"SC Mayo","year":"2011","unstructured":"Mayo SC, de Jong MC, Bloomston M, Pulitano C, Clary BM, Reddy SK, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011;18:3657\u20133665.","journal-title":"Ann Surg Oncol."},{"key":"6433_CR31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1677\/erc.1.01017","volume":"12","author":"F Panzuto","year":"2005","unstructured":"Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083\u20131092.","journal-title":"Endocr Relat Cancer."},{"key":"6433_CR32","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/sj.bjc.6602825","volume":"93","author":"LM Forrest","year":"2005","unstructured":"Forrest LM, McMillan DC, McArdle CS, Dunlop DJ. An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2005;93: 977\u2013978.","journal-title":"Br J Cancer."},{"key":"6433_CR33","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/01.sla.0000250438.04393.a8","volume":"245","author":"JC Gutierrez","year":"2007","unstructured":"Gutierrez JC, Perez EA, Moffat FL, Livingstone AS, Franceschi D, Koniaris LG. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Ann Surg. 2007;245: 952\u2013958.","journal-title":"Ann Surg."},{"key":"6433_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/MCG.0b013e3181a9f10a","volume":"44","author":"A Townsend","year":"2010","unstructured":"Townsend A, Price T, Yeend S, Pittman K, Patterson K, Luke C. Metastatic carcinoid tumor: changing patterns of care over two decades. J Clin Gastroenterol. 2010;44: 195\u20139.","journal-title":"J Clin Gastroenterol."},{"key":"6433_CR35","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/jnci\/djn275","volume":"100","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E. Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors. J Natl Cancer Inst. 2008;100:1282\u20131289.","journal-title":"J Natl Cancer Inst."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-018-6433-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-6433-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-6433-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:10:55Z","timestamp":1553040655000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-018-6433-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,20]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["6433"],"URL":"https:\/\/doi.org\/10.1245\/s10434-018-6433-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,20]]},"assertion":[{"value":"25 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"David L. Chan, Matthew Dixon, Calvin H.L. Law, Serge Koujanian, Kaitlyn A. Beyfuss, Simron Singh, Sten Myrehaug, and Julie Hallet have no commercial interests to declare for this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}